Ο Οργανισμός Τροφίμων και Φαρμάκων των ΗΠΑ (FDA) ενέκρινε το nivolumab (Opdivo, Bristol Myers Squibb) με ipilimumab (Yervoy, Bristol Myers Squibb) ως θεραπεία πρώτης…
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial
admin - On no comment on Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial
7 mins, 17 s Summary
Background
Breast-conserving surgery, adjuvant systemic therapy, and radiotherapy are the standard of care for most women with early breast cancer. There are few reports of clinical outcomes beyond the first decade of follow-up of randomised trials comparing breast-conserving surgery with or without radiotherapy. We present a 30-year update of the Scottish Breast Conservation Trial.
Methods
In this randomised, controlled, phase 3 trial across 14 hospitals in Scotland, women aged younger than 70 years with early breast cancer (tumours ≤4 cm [T1 or T2 and N0 or N1]) were included. They underwent breast-conserving surgery (1 cm margin) with axillary node sampling or clearance. Oestrogen receptor (ER)-rich patients (≥20 fmol/mg protein) received 20 mg oral tamoxifen daily for 5 years. ER-poor patients (<20 fmol/mg protein) received chemotherapy (cyclophosphamide 600 mg/m2, methotrexate 50 mg/m2, and fluorouracil 600 mg/m2 every 21 days intravenously in eight courses). Stratification was by menstrual status (within or more than 12 months from last menstrual period) and ER status (oestrogen concentration ≥20 fmol/mg protein, <20 fmol/mg protein, or unknown) and patients were randomly assigned (1:1) to high-dose (50 Gy in 20–25 fractions) local or locoregional radiotherapy versus no radiotherapy. No blinding was possible due to the nature of the treatment. We report the primary endpoint of the original trial, ipsilateral breast tumour recurrence, and the co-primary endpoint, overall survival. Clinical outcomes were compared by the log-rank test. Hazard ratios (HRs) are reported, with no radiotherapy as the reference group. Failures of the proportional hazards assumption are reported if significant. All analyses are by intention to treat.
Findings
Between April 1, 1985, and Oct 2, 1991, 589 patients were enrolled and randomly assigned to the two treatment groups (293 to radiotherapy and 296 to no radiotherapy). After exclusion of four ineligible patients (two in each group), there were 291 patients in the radiotherapy group and 294 patients in the no radiotherapy group. Median follow-up was 17·5 years (IQR 8·4–27·9). Ipsilateral breast tumour recurrence was significantly lower in the radiotherapy group than in the no radiotherapy group (46 [16%] of 291 vs 107 [36%] of 294; HR 0·39 [95% CI 0·28–0·55], p<0·0001). Although there were differences in the hazard rate for ipsilateral breast tumour recurrence in the first decade after treatment (HR 0·24 [95% CI 0·15–0·38], p<0·0001), subsequent risks of ipsilateral breast tumour recurrence were similar in both groups (0·98 [0·54–1·79], p=0·95). There was no difference in overall survival between the two groups (median 18·7 years [95% CI 16·5–21·5] in the no radiotherapy group vs 19·2 years [16·9–21·3] in the radiotherapy group; HR 1·08 [95% CI 0·89–1 ·30], log-rank p=0·43).
Interpretation
Our findings suggest that patients whose biology predicts a late relapse a decade or more after breast-conserving surgery for early breast cancer might gain little from adjuvant radiotherapy.
Funding
Breast Cancer Institute (part of Edinburgh and Lothian Health Foundation) and PFS Genomics (now part of Exact Sciences).
Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00347-4/abstract
References
- 1.
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.N Engl J Med. 1995; 333: 1456-1461View in Article
- Fisher B
- Anderson S
- Redmond CK
- Wolmark N
- Wickerham DL
- Cronin WM
- 2.
10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial.J Clin Oncol. 1999; 17: 2326-2333View in Article
- Liljegren G
- Holmberg L
- Bergh J
- et al.
- 3.
Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update.J Natl Cancer Inst. 1996; 88: 1659-1664View in Article
- Clark RM
- Whelan T
- Levine M
- et al.
- 4.
Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial.Lancet. 1996; 348: 708-713View in Article
- Forrest AP
- Stewart HJ
- Everington D
- et al.
- 5.
Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients.Eur J Cancer. 1995; 31A: 1574-1579View in Article
- Veronesi U
- Salvadori B
- Luini A
- et al.
- 6.
National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancer of one centimeter or less.J Clin Oncol. 2002; 20: 4141-4149View in Article
- Fisher B
- Bryant J
- Dignam JJ
- et al.
- 7.
Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening.Eur J Cancer. 2003; 39: 1690-1697View in Article
- Malmström P
- Holmberg L
- Anderson H
- et al.
- 8.
Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence.Eur J Cancer. 2010; 46: 95-101View in Article
- Winzer KJ
- Sauerbrei W
- Braun M
- et al.
- 9.
Breast conservation treatment with radiation: an ongoing success story.J Clin Oncol. 2010; 28: 709-711View in Article
- Solin LJ
- 10.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.Lancet. 2011; 378: 1707-1716View in Article
- Darby S
- McGale P
- Correa C
- et al.
- 11.
The importance of long-term follow up of participants in clinical trials.Br J Cancer. 2023; 128: 432-438View in Article
- Cuzick J
- 12.
Sisyphean efforts: establishing the correct risk-benefit balance for adjuvant therapies.J Clin Oncol. 2016; 34: 895-897View in Article
- Bergh J
- Pritchard KI
- Cameron D
- 13.
Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer.N Engl J Med. 2002; 347: 1227-1232View in Article
- Veronesi U
- Cascinelli N
- Mariani L
- et al.
- 14.
Checking the Cox model with cumulative sums of Martingale-based residuals.Biometrika. 1993; 80: 557-572View in Article
- Lin DY
- Wei LJ
- Ying Z
- 15.
Breast-conserving surgery without radiation therapy for invasive cancer.Clin Breast Cancer. 2021; 21: 112-119View in Article
- Montagna G
- Morrow M
- 16.
NSABP breast cancer clinical trials: recent results and future directions.Clin Med Res. 2003; 1: 309-326View in Article
- Mamounas EP
- 17.
No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.Eur J Cancer. 2016; 67: 57-65View in Article
- Killander F
- Karlsson P
- Anderson H
- et al.
- 18.
Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med. 2002; 347: 1233-1241View in Article
- Fisher B
- Anderson S
- Bryant J
- et al.
- 19.
Validation of Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) in early-stage invasive breast cancer patients of the Scottish Conservation Trial.Cancer Res. 2023; 83 (P4-02-12 (abstr).)View in Article
- Taylor KJ
- Bartlett JMS
- Bennett J
- et al.
- 20.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.Lancet. 2011; 378: 771-784View in Article
- Davies C
- Godwin J
- Gray R
- et al.
- 21.
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.Lancet. 2013; 381: 805-816View in Article
- Davies C
- Pan H
- Godwin J
- et al.
- 22.
aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer.Proc Am Soc Clin Oncol. 2013; 31 (abstr).: 5View in Article
- Gray RGRD
- Rea D
- Handley K
- et al.
- 23.
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.Lancet Oncol. 2021; 22: 1139-1150View in Article
- Bradley R
- Braybrooke J
- Gray R
- et al.
- 24.
Risk of ischemic heart disease in women after radiotherapy for breast cancer.N Engl J Med. 2013; 368: 987-998View in Article
- Darby SC
- Ewertz M
- McGale P
- et al.
- 25.
Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: can radiotherapy ever be safely withheld?.Radiother Oncol. 2009; 90: 14-22View in Article
- Mannino M
- Yarnold JR
- 26.
Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomised trial.Ann Oncol. 2001; 12: 997-1003View in Article
- Veronesi U
- Marubini E
- Mariani L
- et al.
